Typing of Human Papilloma Virus (HPV) From Female Genital Warts

This study has been completed.

Sponsor:

Collaborator:

Merck

Information provided by (Responsible Party):

Shahila Tayib, University of Cape Town

ClinicalTrials.gov Identifier:

NCT01192282

First received: August 31, 2010

Last updated: January 18, 2013

Last verified: January 2013

History of Changes

Results First Received: December 15, 2012

Study Type:	Observational
Study Design:	Observational Model: Cohort; Time Perspective: Prospective
Conditions:	Genital Warts Human Papilloma Virus
Intervention:	Procedure: Medical / Surgical Treatment

Participant Flow

Show Participant Flow

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
New Cases	Newly diagnosed cases of genital warts
Recurrent Cases	Reappearance of genital warts at 3 or 6 months post-treatment in participants free of warts at completion of treatment
Persistent Cases	The warts presence after completion of treatment
Total	Total of all reporting groups

Baseline Measures

	New Cases	Recurrent Cases	Persistent Cases	Total
Number of Participants [units: participants]	94	40	22	156
Age, Customized [units: Years] Mean ( Full Range )	28.64 ( 15 to 53 )	30.18 ( 18 to 49 )	29.91 ( 17 to 50 )	29.21 ( 15 to 53 )
Gender [units: Partcipants]
Female	94	40	22	156
Male	0	0	0	0
Marital Status [units: Participants]
Single, Not Sexually Active	19	6	5	30
Single, Sexually Active	56	27	9	92
Married	13	4	4	21
Separated / Divorced / Widow	6	3	4	13
Age at First Sexual Intercourse [units: Participants]
14 or Less (Years)	9	2	1	12
15 - 19 (Years)	69	33	14	116
20 and Above (Years)	16	5	6	27
Virgo Intacta (Years)	0	0	1	1
Education Level [units: Participants]
Primary	13	0	3	16
Secondary	67	36	13	116
Tertiary	14	4	6	24
Smoking [units: Participants]
Yes	9	3	4	16
No	77	34	15	126
Previously	8	3	3	14
HIV Status [units: Participants]
Positive	71	36	16	123
Negative	21	3	5	29
Unknown	2	1	1	4
Treatment Modalities [units: Participants]
Local Ablation with Tricholoroacetic Acid (TCA)	7	2	2	11
Electrocautery under LA	68	28	13	109
Electrocautery / Laser Ablation under GA	17	9	7	33
TCA + Electrocautery	2	1	0	3

Outcome Measures

Show All Outcome Measures

1. Primary:

HPV DNA and HIV Status [ Time Frame: 18 Months ]

Show Outcome Measure 1

2. Primary:

HPV DNA and Pap Smear Results [ Time Frame: 18 Months ]

Show Outcome Measure 2

3. Primary:

Number of HPV Genotypes Isolated by HIV Status [ Time Frame: Up to 18 months ]

Show Outcome Measure 3

4. Primary:

Commonest HPV Genotypes Isolated by HIV Status [ Time Frame: 18 months ]

Show Outcome Measure 4

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Thirty (19.2%) specimens had to be rejected due to contamination that occurred during the analysis process. During the HPV DNA analysis, there were protocols for different aspect of controls during the analysis which needed to be negative.

Results Point of Contact:

Name/Title: Dr Shahila Tayib
Organization: Groote Schurr Hospital / University of Cape Town
phone: 0060195773376
e-mail: syarq@yahoo.com

No publications provided

Responsible Party:	Shahila Tayib, University of Cape Town
ClinicalTrials.gov Identifier:	NCT01192282 History of Changes
Other Study ID Numbers:	131/2010
Study First Received:	August 31, 2010
Results First Received:	December 15, 2012
Last Updated:	January 18, 2013
Health Authority:	South Africa: Human Research Ethics Committee

To Top